<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CEP</journal-id>
<journal-title-group>
<journal-title>Clinical and Experimental Pediatrics</journal-title><abbrev-journal-title>Clin Exp Pediatr</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2713-4148</issn>
<publisher>
<publisher-name>Korean Pediatric Society</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3345/cep.2025.00577</article-id>
<article-id pub-id-type="publisher-id">cep-2025-00577</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
<subj-group subj-group-type="heading">
<subject>Infection</subject>
</subj-group></subj-group></article-categories>
<title-group>
<article-title>Association between vitamin D polymorphisms and binding protein and COVID-19 risk and severity in children</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0009-0005-6020-9708</contrib-id>
<name><surname>Giatraki</surname><given-names>Victoria</given-names></name>
<degrees>MD</degrees>
<degrees>MSc</degrees>
<xref ref-type="aff" rid="af1-cep-2025-00577"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2025-00577"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9142-907X</contrib-id>
<name><surname>Dimitriou</surname><given-names>Helen</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="af2-cep-2025-00577"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3499-3605</contrib-id>
<name><surname>Martimianaki</surname><given-names>Georgia</given-names></name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="af2-cep-2025-00577"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1214-4151</contrib-id>
<name><surname>Tsatsanis</surname><given-names>Christos</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="af3-cep-2025-00577"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8456-5292</contrib-id>
<name><surname>Galanakis</surname><given-names>Emmanouil</given-names></name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="af1-cep-2025-00577"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2025-00577"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5530-5704</contrib-id>
<name><surname>Perdikogianni</surname><given-names>Chrysoula</given-names></name>
<degrees>MD</degrees>
<degrees>PhD</degrees>
<xref ref-type="corresp" rid="c1-cep-2025-00577"/>
<xref ref-type="aff" rid="af1-cep-2025-00577"><sup>1</sup></xref>
<xref ref-type="aff" rid="af2-cep-2025-00577"><sup>2</sup></xref>
</contrib>
<aff id="af1-cep-2025-00577">
<label>1</label>Department of Paediatrics, University Hospital of Heraklion, Medical School University of Crete, Crete, <country>Greece</country></aff>
<aff id="af2-cep-2025-00577">
<label>2</label>Laboratory of Child’s Health, Division of Mother and Child Health, Medical School University of Crete, Crete, <country>Greece</country></aff>
<aff id="af3-cep-2025-00577">
<label>3</label>Laboratory of Clinical Chemistry, Department of Laboratory Medicine, Medical School University of Crete, Crete, <country>Greece</country></aff>
</contrib-group>
<author-notes>
<corresp id="c1-cep-2025-00577">Corresponding author: Chrysoula Perdikogianni, MD, PhD. Department of Paediatrics, University Hospital of Heraklion, Medical School University of Crete, Greece Email: <email>perdikogian@uoc.gr</email></corresp>
</author-notes>
<pub-date pub-type="collection">
<month>12</month>
<year>2025</year></pub-date>
<pub-date pub-type="epub">
<day>22</day>
<month>10</month>
<year>2025</year></pub-date>
<volume>68</volume>
<issue>12</issue>
<fpage>998</fpage>
<lpage>1006</lpage>
<history>
<date date-type="received">
<day>9</day>
<month>03</month>
<year>2025</year></date>
<date date-type="rev-recd">
<day>1</day>
<month>07</month>
<year>2025</year></date>
<date date-type="accepted">
<day>18</day>
<month>09</month>
<year>2025</year></date>
</history>
<permissions>
<copyright-statement>Copyright &#x000a9; 2025 by The Korean Pediatric Society</copyright-statement>
<copyright-year>2025</copyright-year>
<license>
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions>
<abstract>
<sec><title>Background</title>
<p> The effects of genetic background on the biological effects of vitamin D on coronavirus disease 2019 (COVID-19) in children remain unclear.</p></sec>
<sec><title>Purpose</title>
<p> This study aimed to explore the association between vitamin D-related genetic background and 25-hydroxyvitamin D status and COVID-19 occurrence and severity in children. Here we explored key genetic variants within the vitamin D pathway in pediatric COVID-19 patients in relation to circulating vitamin D binding protein (VDBP).</p></sec>
<sec><title>Methods</title>
<p> Sixty children aged 0&#x02013;14 years with severe acute respiratory syndrome coronavirus 2 infection and 60 matched controls were genotyped for the vitamin D receptor (VDR) gene (<italic>FokI</italic>, <italic>BsmI</italic>, <italic>TaqI</italic>, <italic>ApaI</italic>), Gc gene of VDBP (<italic>rs7041</italic>, <italic>rs4588</italic>), and CYP27B1 promoter (<italic>rs10877012</italic>) single nucleotide polymorphisms by polymerase chain reaction and restriction fragment length polymorphism assay.</p></sec>
<sec><title>Results</title>
<p> The FokI FF genotype was more frequently identified among COVID-19 patients than controls, among whom the <italic>TaqI TT</italic> genotype was prevalent (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.08&#x02013;4.73; <italic>P</italic>&#x0003d;0.02; and OR, 0.29; 95% CI, 0.13&#x02013;0.63; <italic>P</italic>&#x0003d;0.001, respectively). The <italic>Gc1F</italic> haplotype was significantly more represented in controls versus COVID-19 patients (OR, 0.39; 95% CI, 0.19&#x02013;0.81; <italic>P</italic>&#x0003d;0.01). A 2.04-fold increased risk of COVID-19 was observed in the presence of the VDR <italic>FokI F</italic> allele (OR, 2.04; 95% CI, 1.14&#x02013;3.64; <italic>P</italic>&#x0003d;0.01). A multivariate analysis revealed a significant association between the <italic>FokI FF</italic> genotype and disease severity (OR, 0.20; 95% CI, 0.04&#x02013;0.83; <italic>P</italic>&#x0003d;0.02). Serum VDBP levels were similar between groups.</p></sec>
<sec><title>Conclusion</title>
<p> The <italic>FF</italic> genotype of the VDR <italic>FokI</italic> polymorphism may be associated with COVID-19 and have a significant clinical impact on disease severity in children.</p></sec>
</abstract>
<kwd-group>
<kwd>COVID-19</kwd>
<kwd>Vitamin D receptor</kwd>
<kwd>Vitamin D binding protein</kwd>
<kwd>CYP27B1</kwd>
<kwd>Single nucleotide polymorphism</kwd>
</kwd-group>
</article-meta>
<notes>
<title>Key message</title>
<boxed-text>
<p><bold>Question:</bold> Addressing crucial genetic variants within the vitamin D pathway and coronavirus disease 2019 (COVID-19) susceptibility, the vitamin D receptor, vitamin D binding protein, and CYP27B1-1260 polmorphisms might be associated with COVID-19 occurrence and severity in children.</p>
<p><bold>Finding:</bold> The <italic>FokI FF</italic> genotype might be an independent risk factor for COVID-19 severity in childhood.</p>
<p><bold>Meaning:</bold> This research may further elucidate genetic susceptibility to multisystem viral infections and establish genetic markers for severe clinical outcomes.</p>
</boxed-text>
</notes></front>
<body>
<p><xref rid="f2-cep-2025-00577" ref-type="fig"/></p>
<p><bold>Graphical abstract.</bold> COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; VDBP, vitamin D binding protein.</p>
<sec sec-type="intro">
<title>Introduction</title>
<p>Genetic variants in the vitamin D pathway have been linked to children&#x02019;s susceptibility to viral respiratory infections, suggesting a possible role of vitamin D as an immune modulator &#x0005b;<xref ref-type="bibr" rid="b1-cep-2025-00577">1</xref>,<xref ref-type="bibr" rid="b2-cep-2025-00577">2</xref>&#x0005d;. Unregulated inflammatory responses and cytokine storm, involved in the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may be therefore associated with vitamin D status and genetic background &#x0005b;<xref ref-type="bibr" rid="b3-cep-2025-00577">3</xref>,<xref ref-type="bibr" rid="b4-cep-2025-00577">4</xref>&#x0005d;. Genetic susceptibility may predispose to the infection or disease progression and although coronavirus disease 2019 (COVID-19) is typically mild in children, serious illness has been reported and very few of them may develop severe complications &#x0005b;<xref ref-type="bibr" rid="b5-cep-2025-00577">5</xref>,<xref ref-type="bibr" rid="b6-cep-2025-00577">6</xref>&#x0005d;.</p>
<p>Recent data have demonstrated the strong effect of vitamin D on the gene expression of antimicrobial peptides, regulating innate and acquired immune responses as well as the inflammatory cascade &#x0005b;<xref ref-type="bibr" rid="b1-cep-2025-00577">1</xref>,<xref ref-type="bibr" rid="b2-cep-2025-00577">2</xref>&#x0005d;. Its biological actions are executed through the vitamin D receptor (VDR) and the vitamin D binding protein (VDBP), the major vitamin D carrier which binds over 99% of the circulating vitamin D metabolites &#x0005b;<xref ref-type="bibr" rid="b1-cep-2025-00577">1</xref>,<xref ref-type="bibr" rid="b7-cep-2025-00577">7</xref>&#x0005d;. 25-hydroxyvitamin D (25&#x0005b;OH&#x0005d;D), the major circulating form of vitamin D, is converted to the active form of 1,25-dihydroxyvitamin D (1,25&#x0005b;OH&#x0005d;2D) through the mitochondrial 1 &#x003b1;-hydroxylase enzyme (CYP27B1) &#x0005b;<xref ref-type="bibr" rid="b1-cep-2025-00577">1</xref>,<xref ref-type="bibr" rid="b7-cep-2025-00577">7</xref>&#x0005d;. Multiple cell populations of innate immunity, including respiratory epithelial cells, macrophages, and dendritic cells, in which these genes are expressed, are required to convert circulating plasma 25(OH)D to the active form 1,25(OH)2D &#x0005b;<xref ref-type="bibr" rid="b8-cep-2025-00577">8</xref>&#x0005d;. Moreover, 1,25(OH)2D induces the expression of genes encoding antimicrobial peptides such as the host defence cathelicidin antimicrobial peptide, which is a key component of antiviral responses acting as a regulator of immune response and enhances antimicrobial effects against various pathogens through induction of autophagy &#x0005b;<xref ref-type="bibr" rid="b7-cep-2025-00577">7</xref>,<xref ref-type="bibr" rid="b9-cep-2025-00577">9</xref>&#x0005d;.</p>
<p>Genetic changes in genes involved in the metabolism, transport or binding of vitamin D may result in its deficiency &#x0005b;<xref ref-type="bibr" rid="b10-cep-2025-00577">10</xref>&#x0005d;. Single nucleotide polymorphisms (SNPs) of the gene encoding VDR (<italic>FokI, BsmI, ApaI, TaqI</italic>), the Gc gene of VDBP (<italic>rs4588</italic> and <italic>rs7041</italic>) and the CYP27B1-1260 (<italic>rs10877012</italic>), as well as vitamin D deficiency as a result of low levels of VDBP in plasma have been suggested to be associated with an increased risk of respiratory viral infections in children, which supports the possible role of vitamin D in the immune response to viral respiratory infections &#x0005b;<xref ref-type="bibr" rid="b8-cep-2025-00577">8</xref>,<xref ref-type="bibr" rid="b10-cep-2025-00577">10</xref>,<xref ref-type="bibr" rid="b11-cep-2025-00577">11</xref>&#x0005d;.</p>
<p>To date, the role of vitamin D deficiency in the susceptibility of children to COVID-19 is still under investigation but has been linked to clinical severity of the infection in children and higher levels of inflammation markers &#x0005b;<xref ref-type="bibr" rid="b12-cep-2025-00577">12</xref>,<xref ref-type="bibr" rid="b13-cep-2025-00577">13</xref>&#x0005d;. Recent research in adults has shown that VDR gene polymorphisms might play critical role in the COVID-19 severity &#x0005b;<xref ref-type="bibr" rid="b14-cep-2025-00577">14</xref>&#x0005d;. Given the sparse data on the impact of vitamin D pathway components in disease in children, the aim of this study was to investigate the role of the genetic variants related to the status and bioavailability of vitamin D, in the susceptibility of children to COVID-19 and the association of the different genotypes with the disease severity.</p>
</sec>
<sec sec-type="methods">
<title>Methods</title>
<sec>
<title>1. Study population</title>
<p>This prospective case-control clinical laboratory study included 60 infants, children and adolescents age 1 month to 14 years who were admitted to the hospital from October 2021 through July 2022 due to confirmed SARS-CoV-2 infection by real-time reverse transcription-polymerase chain reaction (RT-PCR) assay from nasopharyngeal swab samples. Patients were further categorized into mild, moderate, severe, and critical subgroups according to recently published classifications &#x0005b;<xref ref-type="bibr" rid="b15-cep-2025-00577">15</xref>,<xref ref-type="bibr" rid="b16-cep-2025-00577">16</xref>&#x0005d;, as follows:</p>
<sec>
<title>1) Mild illness</title>
<p>Individuals with COVID-19-related symptoms, including fever/chills, cough, vomiting, diarrhea, etc. without signs of pneumonia, abnormal chest imaging, or shortness of breath.</p>
</sec>
<sec>
<title>2) Moderate illness</title>
<p>Cases presented with respiratory symptoms, with or without fever, age-specific tachypnea or chest imaging indicating pneumonia. Illness indicative of moderate severity also included dehydration, gastroenteritis and use of intravenous fluids at admission or during hospitalization.</p>
</sec>
<sec>
<title>3) Severe illness and critically ill cases</title>
<p>Individuals with dyspnea, hypoxia (SpO<sub>2</sub>&lt;93%), acute respiratory distress syndrome, acute kidney injury or liver failure, myocarditis, pericarditis, disturbed consciousness and coagulation dysfunction. Patients who required intensive care unit monitoring or support, invasive or noninvasive mechanical ventilation.</p>
<p>Demographic characteristics and medical history of the patients, including age, weight status and body mass index (BMI), vaccination status, time of infection and the presence of comorbidities was obtained. Exclusion criteria included asymptomatic COVID-19 cases and patients with chronic debilitating medical conditions (e.g., malignancy, immunodeficiency, cystic fibrosis, chronic renal disease or patients receiving immunosuppressive therapy). BMI could not be assessed for all participants due to age-related limitations; instead, weight status was evaluated based on available clinical information. Due to limited vaccination coverage during the study period and at the time of patient recruitment, COVID-19 vaccination status was not incorporated into the analysis.</p>
<p>Sixty healthy children of matched age, sex and season of enrolment, who were examined in the context of routine check-ups, hospitalization for noninfectious reasons (e.g., accidents, infantile hemangiomas workup) or preoperative assessment, were recruited as a control group. Only asymptomatic controls, tested negative for SARS-CoV-2 by RT-PCR, and for whom there was no history of COVID-19 infection or recent contact with a COVID-19 case at the time of blood sampling, were included.</p>
<p>Data on race and ethnicity was obtained from patients/family report. Analysis did not include distribution of patients according to different ethnic groups.</p>
</sec>
</sec>
<sec>
<title>2. Sampling procedure and genetic analysis</title>
<p>Peripheral whole blood and serum samples were collected from patients and controls upon admission and were stored at -20&#x02103; until further analysis. Genomic DNA was extracted from peripheral blood lymphocytes using the PureLink Genomic DNA Mini Kit (Invitrogen, USA) according to the manufacturer&#x02019;s protocol and was stored at -20&#x02103; before genotyping. All participants were genotyped for the VDR <italic>FokI</italic> (<italic>rs10735810</italic>), <italic>BsmI</italic> (<italic>rs1544410</italic>), <italic>ApaI</italic> (<italic>rs7975232</italic>), <italic>TaqI</italic> (<italic>rs731236</italic>), Gc (<italic>rs7041, rs4588</italic>) and the CYP27B1-1260 promoter polymorphism (<italic>rs10877012</italic>), by DNA amplification with PCR and sequence-specific oligonucleotide primers followed by the restriction fragment length polymorphism (RFLP) assay, as previously described &#x0005b;<xref ref-type="bibr" rid="b11-cep-2025-00577">11</xref>&#x0005d;.</p>
<p>Representative agarose gel electrophoresis of the PCR-RFLP products of the studied SNPs are presented in <xref ref-type="supplementary-material" rid="SD2-cep-2025-00577">Supplementary Figs. 1</xref>-<xref ref-type="supplementary-material" rid="SD4-cep-2025-00577">3</xref>.</p>
</sec>
<sec>
<title>3. Quantitative determination of serum VDBP levels</title>
<p>Serum samples were centrifuged and aliquots were stored at -20&#x02103; until further analysis. VDBP concentration was evaluated in the serum of 83 patients in total (40 index and 43 control cases), using enzyme-linked immunosorbent assay technique (Quantikine ELISA kit, Bio-techne R&amp;D Systems, USA). The normal reference range for VDBP levels was considered as 300&#x02013;600 &#x003bc;g/mL according to published data &#x0005b;<xref ref-type="bibr" rid="b17-cep-2025-00577">17</xref>&#x0005d;.</p>
</sec>
<sec>
<title>4. Statistical analysis</title>
<p>Results are expressed as mean&#x000b1;standard deviation. Comparison of independent and continuous parameters was performed using the Mann-Whitney <italic>U</italic> test. The Kruskal-Wallis test was used for comparison between 3 or more continuous variables. Pearson chi-square test was applied for associations of polymorphisms distribution and allele frequencies of COVID-19 patients and control cases. Variations in the genotype frequencies from the Hardy-Weinberg equilibrium (HWE) were assessed in the control group. Logistic regression analysis was used to calculate the odds ratio (OR) with a confidence interval (CI) of 95% for differences in the genotypes of the selected SNPs and to evaluate independent associations between genotypes and COVID-19 susceptibility and severity. Multivariable analysis was applied to further analyze the correlations of the studied parameters with COVID-19 disease and severity after adjusting for the possible confounding factors. Due to the small number of participants with severe COVID-19, they were combined into one group along with those with moderate disease in logistic regression analysis. A <italic>P</italic> value of &lt;0.05 was considered as statistically significant. The sample size was determined with a Sample Size Calculator (G&#x0002a; Power 3.1.9.6).</p>
</sec>
<sec>
<title>5. Ethics</title>
<p>The study protocol was approved by the Ethics committee and the Institutional Review Board of the University Hospital of Heraklion (19654/01-12-2021). The study was conducted in accordance with relevant regulations. Written parental informed consents were obtained from the participants before enrolment.</p>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>In total, 60 patients with laboratory-confirmed COVID-19 and 60 healthy control subjects were enrolled. Demographic characteristics and clinical parameters of the index and control cases are presented in <xref rid="t1-cep-2025-00577" ref-type="table">Table 1</xref>. Index cases and controls did not differ significantly in the matter of age and sex distribution. Patients&#x02019; median age was 5.22&#x000b1;5.47)years, and 33 (55%) were males. Twelve out of 20 patients (60%) with mild disease, were &lt;3 months of age, while 5 out of 10 severe cases were &gt;5 years old. Lowest age in severe COVID-19 group was 2 years. Eleven out of 60 children had comorbidities, such as known asthma, allergic rhinitis, allergic dermatitis (7 patients), type 1 diabetes mellitus (1 patient), history of seizures (2 patients), and hypercholesterolemia (1 patient). Six children were identified as overweight, 2 of whom had coexisting asthma; no cases of obesity were recorded.</p>
<p>Distribution of the VDR (<italic>FokI, TaqI, BsmI, ApaI</italic>), CYP27B1-1260 (<italic>rs10877012</italic>) genotype and allele frequencies in addition to the <italic>Gc rs7041</italic> and <italic>rs4588</italic> variants encoding the 3 major haplotypes (Gc1F, Gc1S, and Gc2) of VDBP in patients and controls are presented in <xref ref-type="supplementary-material" rid="SD1-cep-2025-00577">Supplementary Table 1</xref>. Comparing genotype distribution of the VDR SNPs between the 2 study groups, a statistically significant difference was found in FokI homozygous <italic>FF</italic> genotype (OR, 2.26; 95% CI, 1.08&#x02013;4.73; <italic>P</italic>&#x0003d;0.02) and <italic>TaqI</italic> TT genotype cases (OR, 0.29; 95% CI, 0.13&#x02013;0.63; <italic>P</italic>&#x0003d;0.001). The <italic>FokI f</italic> and <italic>TaqI T</italic> alleles were significantly more represented in controls compared to the COVID-19 group (35% vs. 20.8%; OR, 0.48; 95% CI, 0.27&#x02013;0.87; <italic>P</italic>&#x0003d;0.01), (69.2% vs. 49.2%; OR, 0.43; 95% CI, 0.25&#x02013;0.73; <italic>P</italic>&#x0003d;0.001), respectively. <italic>Gc1F</italic> (<italic>rs7041T-rs4588C</italic>) haplotype was significantly more represented in controls compared to the COVID-19 group (23.3% vs. 10.8%; OR, 0.39; 95% CI, 0.19&#x02013;0.81; <italic>P</italic>&#x0003d;0.01). Patients carrying the <italic>CYP27B1-1260</italic> promoter (rs10877012) A allele constitute the 21.7% of COVID-19 cases as opposed to the 33.3% of control cases (OR, 0.55; 95% CI, 0.31&#x02013;0.98; <italic>P</italic>&#x0003d;0.04). However, no significant difference was found in the polymorphism genotype distribution between the 2 groups.</p>
<p>Genotype distribution of the studied SNPs was evaluated in terms of COVID-19 clinical severity (<xref rid="t2-cep-2025-00577" ref-type="table">Table 2</xref>). The <italic>FokI FF</italic> genotype was found to be more frequent among children with moderate or severe COVID-19 with a statistically significant association noted in the dominant model of analysis (OR, 0.21; 95% CI, 0.05&#x02013;0.85; <italic>P</italic>&#x0003d;0.02). In addition, a moderately significant correlation of Gc (<italic>rs7041</italic>) polymorphism with COVID-19 severity was observed, in the recessive analysis model (OR, 0.31; 95% CI, 0.10&#x02013;0.99; <italic>P</italic>&#x0003d;0.04).</p>
<p>Multivariable logistic regression analysis was performed to further test for associations of COVID-19 infection risk and severe disease with the VDR <italic>FokI FF</italic> genotype, which were demonstrated in the dominant univariable analysis model. The <italic>FokI homozygous FF</italic> genotype was found to constitute an independent risk factor for COVID-19 clinical severity in the univariable logistic regression analysis and after adjusting for comorbidities (e.g., asthma), age and sex parameters (adjusted OR, 0.20; 95% CI, 0.04&#x02013;0.83; <italic>P</italic>&#x0003d;0.02) (<xref rid="t3-cep-2025-00577" ref-type="table">Table 3</xref>). A 2.04-fold increased risk for COVID-19 infection was observed in the case of the VDR FokI F allele (OR, 2.04; 95% CI, 1.14&#x02013;3.64; <italic>P</italic>&#x0003d;0.01). In addition, the allele was moderately significantly correlated with clinical severity (OR, 3.20; 95% CI, 1.01&#x02013;10.0; <italic>P</italic>&#x0003d;0.04) and following the inclusion of additional covariates, this finding was further confirmed in the multivariable analysis (OR, 3.31; 95% CI, 1.02&#x02013;10.7; <italic>P</italic>&#x0003d;0.04).</p>
<p>No statistically significant difference was found between serum VDBP levels of the COVID-19 group and the control group (348.90&#x000b1;133.64 &#x003bc;g/mL, and 340.07&#x000b1;147.56 &#x003bc;g/mL respectively, <italic>P</italic>&#x0003d;0.97). The 3 possible genotypes of Gc SNPs <italic>rs7041</italic> and <italic>rs4588</italic>, were compared regarding the patients&#x02019; serum VDBP, and no significant associations were identified according to the analysis between all 3 groups (Kruskal-Wallis <italic>H</italic> test, <italic>P</italic>&#x0003d;0.201 for Gc <italic>rs7041</italic> and <italic>P</italic>&#x0003d;0.964 for rs4588). VDBP levels were found slightly higher in patients carrying the <italic>rs7041 TT</italic> genotype (442.57&#x000b1;167.39 &#x003bc;g/mL) in comparison with the <italic>TG</italic> (328.18&#x000b1;129.57 &#x003bc;g/mL) and <italic>GG</italic> genotype (307.81&#x000b1;109.21 &#x003bc;g/mL) (<xref rid="f1-cep-2025-00577" ref-type="fig">Fig. 1</xref>) and there was no significant difference in the comparison between pairs of groups (Mann-Whitney <italic>U</italic> test, <italic>P</italic>&#x0003d;0.096 for <italic>rs7041 TT</italic> vs. <italic>TG, GG</italic>). The VDBP levels were not correlated with the VDR genotypes of the studied SNPs (Kruskal-Wallis H test, <italic>P</italic>&#x0003d;0.978 for <italic>FokI</italic>, <italic>P</italic>&#x0003d;0.951 for <italic>BsmI</italic>, <italic>P</italic>&#x0003d;0.917 for <italic>TaqI</italic>, <italic>P</italic>&#x0003d;0.773 for <italic>ApaI</italic>), or the CYP27B1 promoter polymorphism (<italic>P</italic>&#x0003d;0.662).</p>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Evidence supports the role of vitamin D as an immunomodulatory agent, which has been shown to balance the inflammatory and macrophage responses, associated with COVID-19 disease &#x0005b;<xref ref-type="bibr" rid="b3-cep-2025-00577">3</xref>,<xref ref-type="bibr" rid="b4-cep-2025-00577">4</xref>&#x0005d;. SNPs of the VDR locus have been suggested to be associated with an increased risk of lower respiratory infections in children and pathogenesis of immune-mediated diseases &#x0005b;<xref ref-type="bibr" rid="b18-cep-2025-00577">18</xref>-<xref ref-type="bibr" rid="b21-cep-2025-00577">21</xref>&#x0005d;. Thus, the hypothesis we aimed to explore is that the vitamin D-related genetic background might be associated with the occurrence and severity of a multisystem viral infection, such as COVID-19, in pediatric patients.</p>
<p>The <italic>FokI</italic> start codon polymorphism in the exon 2 at the 5&#x02032; end of the VDR gene has been associated with susceptibility to viral infections, due to changes in transcriptional activity of the VDR protein and possible effects on immune cell behavior &#x0005b;<xref ref-type="bibr" rid="b3-cep-2025-00577">3</xref>&#x0005d;. In the case of COVID-19 infection, to date, only one study has investigated the VDR <italic>FokI</italic> polymorphism solely in pediatric patients, concluding that the homozygous <italic>FF</italic> genotype may constitute an independent risk factor for susceptibility to COVID-19, whereas the <italic>FokI f</italic> allele may act as a protective factor for the infection &#x0005b;<xref ref-type="bibr" rid="b22-cep-2025-00577">22</xref>&#x0005d;. This finding may be explained by the fact that the <italic>FokI f</italic> allele encodes a different isoform of VDR protein that results in higher serum levels of 25(OH)D, in contrast to the <italic>FokI FF</italic> genotype which encodes a less transcriptionally efficient isoform, possibly influencing immune responses &#x0005b;<xref ref-type="bibr" rid="b23-cep-2025-00577">23</xref>&#x0005d;. This functional effect may provide a possible basis for the observed association of the <italic>FokI FF</italic> genotype and disease severity in children, as it may affect host vulnerability to viral infections, such as COVID-19. Together, the aforementioned observations support our results since the <italic>FokI FF</italic> genotype and the <italic>FokI F</italic> allele were significantly more frequent among COVID-19 patients as well as patients with moderate or severe disease, whereas the VDR <italic>FokI f</italic> allele was more represented in the control group. From the logistic regression analysis of the present study the <italic>FokI FF</italic> genotype was found to constitute an independent risk factor for disease severity, with the FokI F allele associated with both increased susceptibility to COVID-19 and clinical severity. Kotur et al. &#x0005b;<xref ref-type="bibr" rid="b24-cep-2025-00577">24</xref>&#x0005d;, who assessed the significant effect of the variants associated with poor vitamin D status with severe COVID-19 in 120 Serbian COVID-19 patients recruited during the first peak of COVID-19, found no relationship of the infection risk or severity with pediatric patients. In the same study, however, the vast majority of the study population suffered from mild disease, and as such the analysis of variants was limited to the effect in the risk of symptomatic COVID-19 &#x0005b;<xref ref-type="bibr" rid="b24-cep-2025-00577">24</xref>&#x0005d;.</p>
<p>Alteration of the VDR gene expression, the protein structure and stability, may have an effect of the exon 9 <italic>TaqI</italic> polymorphism, leading to reduced signaling and immunomodulatory actions of vitamin D in target cells &#x0005b;<xref ref-type="bibr" rid="b11-cep-2025-00577">11</xref>,<xref ref-type="bibr" rid="b25-cep-2025-00577">25</xref>&#x0005d;. Data provided by a previous case-control study support the link between the VDR <italic>TaqI</italic> variant and the susceptibility to viral respiratory tract infections in hospitalized infants when the polymorphism frequency was assessed in comparison with healthy controls &#x0005b;<xref ref-type="bibr" rid="b11-cep-2025-00577">11</xref>&#x0005d;. These results are concordant with the findings of our study, in which the <italic>TaqI t</italic> allele was significantly more represented in COVID-19 patients, compared to the VDR <italic>TaqI TT</italic> genotype and the <italic>TaqI T</italic> allele that were more frequent in the control group. A recent single-center case-control study in Greece, exploring the associations of the 4 genetic VDR variants (<italic>FokI, BsmI, TaqI</italic>, and <italic>ApaI</italic>) with severity of COVID-19, showed that the <italic>TaqI</italic> CC (polymorphic) genotype constitutes an independent risk factor for COVID-19 severity &#x0005b;<xref ref-type="bibr" rid="b14-cep-2025-00577">14</xref>&#x0005d;. In a similar study investigating the genotypic distributions of <italic>FokI</italic> and <italic>TaqI</italic> variants in 300 COVID-19 positive patients in Cyprus, the polymorphic alleles were statistically more represented in patients with SARS-CoV-2 infection as opposed to the 300 studied controls &#x0005b;<xref ref-type="bibr" rid="b26-cep-2025-00577">26</xref>&#x0005d;. In another cohort study from Turkey, the authors suggested that the VDR gene SNPs including <italic>FokI, TaqI</italic>, and <italic>ApaI</italic>, are independent risk factors for severity and mortality of COVID-19 patients &#x0005b;<xref ref-type="bibr" rid="b27-cep-2025-00577">27</xref>&#x0005d;. In our study, no significant association was evident between the VDR <italic>BsmI</italic> or <italic>ApaI</italic> genotype/allele distribution and COVID-19 risk or, regarding the <italic>TaqI</italic> polymorphism, the disease severity.</p>
<p>Serum concentration of the 25(OH)D is partly affected by the VDBP phenotypes. Given the multiple functions of the VDBP as part of the actin scavenger system, the neutrophil chemotaxis, as a macrophage activation factor (Gc-MAF) and the protective immunomodulatory effect of vitamin D, the association of these variants with COVID-19 clinical course and complications, have been an area of active research interest &#x0005b;<xref ref-type="bibr" rid="b28-cep-2025-00577">28</xref>,<xref ref-type="bibr" rid="b29-cep-2025-00577">29</xref>&#x0005d;. Carriers of specific major VDBP alleles, as such the <italic>Gc2</italic>, have reportedly lower plasma levels of vitamin D metabolites and vitamin D binding protein, which may confer susceptibility to severe COVID-19. Conversely, the <italic>Gc1F</italic> variant has been found to be more common among healthy infants when compared to infants with acute viral respiratory tract infections &#x0005b;<xref ref-type="bibr" rid="b11-cep-2025-00577">11</xref>&#x0005d;. These results are concordant with our findings, regarding the <italic>rs7041 TT</italic> genotype and the combined <italic>Gc1F</italic> (<italic>rs7041T-rs4588C</italic>) haplotype, which was significantly more frequent in healthy controls as opposed to the COVID-19 patients. Besides, recent studies by Speeckaert et al. &#x0005b;<xref ref-type="bibr" rid="b29-cep-2025-00577">29</xref>&#x0005d; and Karcioglu Batur and Hekim &#x0005b;<xref ref-type="bibr" rid="b30-cep-2025-00577">30</xref>&#x0005d; have retrospectively investigated the impact of the VDBP SNPs at <italic>rs7041</italic> and <italic>rs4588</italic> loci, with a reported negative correlation of the <italic>rs7041 TT</italic> genotype and the DBP1 allele frequency with the prevalence and mortality rates of COVID-19, in 10 and 55 countries, worldwide, respectively. These results, may be explained by the differences in vitamin D status and the altered vitamin D affinity due to the effect of VDBP variants.</p>
<p>In an attempt to explain our findings, we explored the circulating levels of VDBP in serum of healthy individuals and COVID-19 patients; however no significant link was found with COVID-19 occurrence, nor in relation to the Gc genetic variants. Laboratory data concerning the effects of vitamin D on host immune responses to SARS-CoV-2 infection in children is limited. Recent data have shown that serum VDBP levels have been found significantly decreased in critically ill adult patients with COVID-19, supporting further research focusing on VDBP role in the pathogenesis of the disease &#x0005b;<xref ref-type="bibr" rid="b31-cep-2025-00577">31</xref>&#x0005d;. To our knowledge, this is the first study exploring the serological status of VDBP in children with COVID-19 disease in relation to the VDBP polymorphisms, as well as the studied SNPs of VDR and CYP27B1 promoter genes. Despite the fact that no significant associations were evident between serum levels and pediatric COVID-19 disease or the Gc genotypes distribution, we speculate the <italic>rs7041 TT</italic> genotype, which was more frequent among our control group, and the Gc1F haplotype, notably having the highest affinity for 25(OH) D, may be associated with the circulating levels of 25(OH) D in blood and consequently, the levels of the bioavailable vitamin D &#x0005b;<xref ref-type="bibr" rid="b32-cep-2025-00577">32</xref>,<xref ref-type="bibr" rid="b33-cep-2025-00577">33</xref>&#x0005d;. Thus, VDBP binding and 25(OH)D affinity along with their potential protective effects could possibly explain our findings regarding the genetic background of the studied population and the VDBP levels, and should be evaluated in further studies addressing their biological influence on COVID-19 disease and severity.</p>
<p>CYP27B1-1260 allelic variation in the promoter region of CYP27B1 hydroxylase, a key enzyme of the vitamin D metabolism, has been associated with Hepatitis C viral infection and endocrine autoimmune diseases in adults, possibly due to the impact on the enzyme activity and the 1,25(OH)2D synthesis &#x0005b;<xref ref-type="bibr" rid="b34-cep-2025-00577">34</xref>,<xref ref-type="bibr" rid="b35-cep-2025-00577">35</xref>&#x0005d;. As opposed to a previous case-control study investigating the CYP27B1 promoter polymorphism, where no difference was found between infants with viral infections and control subjects &#x0005b;<xref ref-type="bibr" rid="b11-cep-2025-00577">11</xref>&#x0005d;, the same variant was significantly more common among COVID-19 cases in our study, in comparison with the healthy controls.</p>
<p>To our knowledge, this is the first case-control study to simultaneously investigate key genetic variants within the vitamin D cascade, including the VDR, the VDBP and the CYP27B1-1260 promoter polymorphisms, in a pediatric population with COVID-19. The functional consequences of the polymorphisms involved in the mentioned 3 elements in vitamin D pathway, are reported to have substantial impact on vitamin D levels and based on the data supporting its protective role and immunomodulatory effects, may confer susceptibility to infections. In the case of COVID-19, notably characterized by a complex interaction between the virus and the host response, involving multiple inflammatory pathways, elucidating the genetic background that comprises proneness to the infection, emerges as crucial.</p>
<p>This study has some limitations. It should be acknowledged that the design of the present study did not include quantitative determination of serum 25(OH)D levels, but rather focused on the investigation of genetic determinants of vitamin D pathway and key functional proteins, such as VDBP. Although recent studies demonstrate that vitamin D deficiency is commonly observed between pediatric COVID-19 patients, this approach was based on the common observation that total serum 25(OH)D levels are subject to several variations including environmental factors, nutrition and seasonality and may not consistently correlate with the occurrence and clinical outcomes in pediatric COVID-19. In an attempt to complement our findings indicating that genetic variants in the VDR, the Gc gene of VDBP and the CYP27B1 promoter genes might act as more stable indicators for COVID-19 occurrence and outcomes in children, we opted to quantify the relatively unexplored circulating levels of VDBP in children, which may better reflect the biologically active vitamin D and bioavailable fraction in vitamin D metabolism, especially in the context of genetic variability.</p>
<p>As only a few children with comorbidities were included in the present study, the potential effect of underlying medical conditions such as asthma and obesity&#x02014;and their possible relation with genetic variants&#x02014;on COVID-19 clinical severity and disease outcomes could not be fully explored. Larger-scale studies may better elucidate these relationships. A further limitation to consider is that, since SARS-CoV-2 serology testing was not performed in the control group, the number of patients that may have had asymptomatic disease before enrolment, cannot not be acknowledged. Thus, the assessment of risk included the probability in relation to the studied variants, of solely symptomatic COVID-19 disease in the current study. The control group represents the distribution of polymorphisms in the general population, highlighting the need for further studies involving control groups with confirmed exposure and matched risk factors, such as vaccination status&#x02014;which was limited during our patient recruitment period. It is worth mentioning that, although we explored the 3 crucial loci related to vitamin D metabolism and conducted a comprehensive genetic analysis between the index cases with age- and sex-matched controls, the main limitation of our study that needs to be acknowledged is the small sample size. Even though the included frequencies of the genotype groups were consistent with the HWE, a small number of individuals in the included subgroups, may be unavoidable subject to linkage disequilibrium. Thus, the link between vitamin D-related genetic variants and COVID-19 disease needs to be established in larger cohort studies. In this context, comparison of our allele and genotype frequencies with previously published data from pediatric populations where available, reports VDR polymorphisms (<italic>FokI, BsmI, TaqI, ApaI</italic>) genotype distributions ranging approximately from 35% to 55% &#x0005b;<xref ref-type="bibr" rid="b36-cep-2025-00577">36</xref>&#x0005d;. Data regarding the minor allele frequency for the GC gene polymorphism rs4588 indicate a frequency of approximately 25% &#x0005b;<xref ref-type="bibr" rid="b37-cep-2025-00577">37</xref>&#x0005d;. These findings suggest that our control group could be representative, despite sample size limitations.</p>
<p>Nevertheless, our findings, in line with other similar studies, indicate that genetic variants of the VDR, the main plasma carrier of 25(OH)D VDBP and the CYP27B1 promoter gene, could establish genetic markers for COVID-19 occurrence and severe clinical outcome, with the VDR <italic>FokI</italic> polymorphism possibly constituting an independent risk factor for clinical severity of the disease in children. On the base of COVID-19 infection and the possible manifestations of the disease, such as the multisystem inflammatory syndrome associated with it, our results could explain the effect of the vitamin D SNPs in multisystem viral infections in children beyond COVID-19. Moreover, this study may provide insights in the genetic profile of vulnerable children and highlight possible disease subgroups based on the vitamin D genotypes.</p>
<p>To conclude, the VDR <italic>FokI, TaqI</italic>, the <italic>rs7041</italic> of Gc gene and the CYP27B1 promoter polymorphisms might predispose to COVID-19 infection and a more severe clinical course in children. The former might constitute an independent risk factor for disease severity. The effect of genetic variants that mediate vitamin D regulation and metabolism, may extent to viral infections beyond COVID-19 and needs to be further explored.</p>
</sec>
</body>
<back>
<sec sec-type="supplementary-material"><title>Supplementary materials</title>
<p>Supplementary Table 1 and Supplementary Figs. 1-3 are available at <ext-link xlink:href="https://doi.org/10.3345/cep.2025.00577" ext-link-type="uri">https://doi.org/10.3345/cep.2025.00577</ext-link>.</p>
<supplementary-material content-type="loca-data" id="SD1-cep-2025-00577">
<label>Supplementary Table 1.</label><caption><p>VDR (FokI, TaqI, BsmI, ApaI), Gc (rs7041 and rs4588) variants encoding the 3 major haplotypes (Gc1F, Gc1S, and Gc2) of VDBP and CYP27B1-1260 (rs10877012) genotype and allele frequencies in patients and controls</p></caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2025-00577-Supplementary-Table-1.pdf"/></supplementary-material>
<supplementary-material content-type="loca-data" id="SD2-cep-2025-00577">
<label>Supplementary Fig. 1.</label><caption><p>Agarose gel electrophoresis of the vitamin D receptor gene polymerase chain reaction-restriction fragment length polymorphism products.</p></caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2025-00577-Supplementary-Fig-1.pdf"/></supplementary-material>
<supplementary-material content-type="loca-data" id="SD3-cep-2025-00577">
<label>Supplementary Fig. 2.</label><caption><p>Agarose gel electrophoresis of the Gc <italic>rs7041</italic> and <italic>rs4588</italic> polymerase chain reaction-restriction fragment length polymorphism products.</p></caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2025-00577-Supplementary-Fig-2.pdf"/></supplementary-material>
<supplementary-material content-type="loca-data" id="SD4-cep-2025-00577">
<label>Supplementary Fig. 3.</label><caption><p>Agarose gel electrophoresis of the CYP27B1-1260 (<italic>rs10877012</italic>) promoter polymerase chain reaction-restriction fragment length polymorphism products.</p></caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="cep-2025-00577-Supplementary-Fig-3.pdf"/></supplementary-material>
</sec>
<fn-group>
<fn fn-type="conflict"><p><bold>Conflicts of interest</bold></p><p>No potential conflict of interest relevant to this article was reported.</p></fn>
<fn fn-type="financial-disclosure"><p><bold>Funding</bold></p><p>This work has been funded by the University of Crete Special Account for Research Funds grant to Chrysoula Perdikogianni (ELKE UOC, Grant No. 4022).</p></fn>
<fn fn-type="other"><p><bold>Acknowledgments</bold></p><p>The authors appreciate the patients and their families for their participation in the study. We also sincerely thank our clinical colleagues for their valuable support throughout the study.</p></fn>
<fn fn-type="participating-researchers"><p><bold>Author contribution</bold></p><p>Conceptualization: VG, EG, CP; Formal analysis: VG; investigation: VG, HD, GM; Supervision: CT, EG, CP; Visualization: VG; Writing – original draft: VG; Writing – review &amp; editing: HD, GM, CT, EG, CP.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="b1-cep-2025-00577">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gombart</surname><given-names>AF</given-names></name>
</person-group>
<article-title>The vitamin D-antimicrobial peptide pathway and its role in protection against infection</article-title>
<source>Future Microbiol</source>
<year>2009</year>
<volume>4</volume>
<fpage>1151</fpage>
<lpage>65</lpage>
</element-citation></ref>
<ref id="b2-cep-2025-00577">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bahrami</surname><given-names>A</given-names></name>
<name><surname>Sadeghnia</surname><given-names>HR</given-names></name>
<name><surname>Tabatabaeizadeh</surname><given-names>SA</given-names></name>
<name><surname>Bahrami- Taghanaki</surname><given-names>H</given-names></name>
<name><surname>Behboodi</surname><given-names>N</given-names></name>
<name><surname>Esmaeili</surname><given-names>H</given-names></name>
<etal/>
</person-group>
<article-title>Genetic and epigenetic factors influencing vitamin D status</article-title>
<source>J Cell Physiol</source>
<year>2018</year>
<volume>233</volume>
<fpage>4033</fpage>
<lpage>43</lpage>
</element-citation></ref>
<ref id="b3-cep-2025-00577">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Abdollahzadeh</surname><given-names>R</given-names></name>
<name><surname>Shushizadeh</surname><given-names>MH</given-names></name>
<name><surname>Barazandehrokh</surname><given-names>M</given-names></name>
<name><surname>Choopani</surname><given-names>S</given-names></name>
<name><surname>Azarnezhad</surname><given-names>A</given-names></name>
<name><surname>Paknahad</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Association of vitamin D receptor gene polymorphisms and clinical/severe outcomes of COVID-19 patients</article-title>
<source>Infect Genet Evol</source>
<year>2021</year>
<volume>96</volume>
<fpage>105098</fpage>
</element-citation></ref>
<ref id="b4-cep-2025-00577">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Peng</surname><given-names>D</given-names></name>
<name><surname>Huang</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
</person-group>
<article-title>Vitamin D levels and clinical outcomes of SARS-CoV-2 Omicron subvariant BA.2 in children: a longitudinal cohort study</article-title>
<source>Front Nutr</source>
<year>2022</year>
<volume>9</volume>
<fpage>960859</fpage>
</element-citation></ref>
<ref id="b5-cep-2025-00577">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ludvigsson</surname><given-names>JF</given-names></name>
</person-group>
<article-title>Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults</article-title>
<source>Acta Paediatr</source>
<year>2020</year>
<volume>109</volume>
<fpage>1088</fpage>
<lpage>95</lpage>
</element-citation></ref>
<ref id="b6-cep-2025-00577">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kabeerdoss</surname><given-names>J</given-names></name>
<name><surname>Pilania</surname><given-names>RK</given-names></name>
<name><surname>Karkhele</surname><given-names>R</given-names></name>
<name><surname>Kumar</surname><given-names>TS</given-names></name>
<name><surname>Danda</surname><given-names>D</given-names></name>
<name><surname>Singh</surname><given-names>S</given-names></name>
</person-group>
<article-title>Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management</article-title>
<source>Rheumatol Int</source>
<year>2021</year>
<volume>41</volume>
<fpage>19</fpage>
<lpage>32</lpage>
</element-citation></ref>
<ref id="b7-cep-2025-00577">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ismailova</surname><given-names>A</given-names></name>
<name><surname>White</surname><given-names>JH</given-names></name>
</person-group>
<article-title>Vitamin D, infections and immunity</article-title>
<source>Rev Endocr Metab Disord</source>
<year>2022</year>
<volume>23</volume>
<fpage>265</fpage>
<lpage>77</lpage>
</element-citation></ref>
<ref id="b8-cep-2025-00577">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gunville</surname><given-names>CF</given-names></name>
<name><surname>Mourani</surname><given-names>PM</given-names></name>
<name><surname>Ginde</surname><given-names>AA</given-names></name>
</person-group>
<article-title>The role of vitamin D in prevention and treatment of infection</article-title>
<source>Inflamm Allergy Drug Targets</source>
<year>2013</year>
<volume>12</volume>
<fpage>239</fpage>
<lpage>45</lpage>
</element-citation></ref>
<ref id="b9-cep-2025-00577">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Aloul</surname><given-names>KM</given-names></name>
<name><surname>Nielsen</surname><given-names>JE</given-names></name>
<name><surname>Defensor</surname><given-names>EB</given-names></name>
<name><surname>Lin</surname><given-names>JS</given-names></name>
<name><surname>Fortkort</surname><given-names>JA</given-names></name>
<name><surname>Shamloo</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Upregulating human cathelicidin antimicrobial peptide LL-37 expression may prevent severe COVID-19 inflammatory responses and reduce microthrombosis</article-title>
<source>Front Immunol</source>
<year>2022</year>
<volume>13</volume>
<fpage>880961</fpage>
</element-citation></ref>
<ref id="b10-cep-2025-00577">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tomei</surname><given-names>S</given-names></name>
<name><surname>Singh</surname><given-names>P</given-names></name>
<name><surname>Mathew</surname><given-names>R</given-names></name>
<name><surname>Mattei</surname><given-names>V</given-names></name>
<name><surname>Garand</surname><given-names>M</given-names></name>
<name><surname>Alwakeel</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>The role of polymorphisms in vitamin D-related genes in response to vitamin D supplementation</article-title>
<source>Nutrients</source>
<year>2020</year>
<volume>12</volume>
<fpage>2608</fpage>
</element-citation></ref>
<ref id="b11-cep-2025-00577">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zacharioudaki</surname><given-names>M</given-names></name>
<name><surname>Messaritakis</surname><given-names>I</given-names></name>
<name><surname>Galanakis</surname><given-names>E</given-names></name>
</person-group>
<article-title>Vitamin D receptor, vitamin D binding protein and CYP27B1 single nucleotide polymorphisms and susceptibility to viral infections in infants</article-title>
<source>Sci Rep</source>
<year>2021</year>
<volume>11</volume>
<fpage>13835</fpage>
</element-citation></ref>
<ref id="b12-cep-2025-00577">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bayramo&#x0011f;lu</surname><given-names>E</given-names></name>
<name><surname>Akko&#x000e7;</surname><given-names>G</given-names></name>
<name><surname>A&#x0011f;ba&#x0015f;</surname><given-names>A</given-names></name>
<name><surname>Akg&#x000fc;n</surname><given-names>&#x000d6;</given-names></name>
<name><surname>Yurdakul</surname><given-names>K</given-names></name>
<name><surname>Sel&#x000e7;uk Duru</surname><given-names>HN</given-names></name>
<etal/>
</person-group>
<article-title>The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital</article-title>
<source>Eur J Pediatr</source>
<year>2021</year>
<volume>180</volume>
<fpage>2699</fpage>
<lpage>705</lpage>
</element-citation></ref>
<ref id="b13-cep-2025-00577">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Y&#x00131;lmaz</surname><given-names>K</given-names></name>
<name><surname>&#x0015e;en</surname><given-names>V</given-names></name>
</person-group>
<article-title>Is vitamin D deficiency a risk factor for COVID-19 in children?</article-title>
<source>Pediatr Pulmonol</source>
<year>2020</year>
<volume>55</volume>
<fpage>3595</fpage>
<lpage>601</lpage>
</element-citation></ref>
<ref id="b14-cep-2025-00577">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tentolouris</surname><given-names>N</given-names></name>
<name><surname>Achilla</surname><given-names>C</given-names></name>
<name><surname>Anastasiou</surname><given-names>IA</given-names></name>
<name><surname>Eleftheriadou</surname><given-names>I</given-names></name>
<name><surname>Tentolouris</surname><given-names>A</given-names></name>
<name><surname>Basoulis</surname><given-names>D</given-names></name>
<etal/>
</person-group>
<article-title>The association of vitamin D receptor polymorphisms with COVID-19 severity</article-title>
<source>Nutrients</source>
<year>2024</year>
<volume>16</volume>
<fpage>727</fpage>
</element-citation></ref>
<ref id="b15-cep-2025-00577">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>ZM</given-names></name>
<name><surname>Fu</surname><given-names>JF</given-names></name>
<name><surname>Shu</surname><given-names>Q</given-names></name>
<name><surname>Chen</surname><given-names>YH</given-names></name>
<name><surname>Hua</surname><given-names>CZ</given-names></name>
<name><surname>Li</surname><given-names>FB</given-names></name>
<etal/>
</person-group>
<article-title>Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus</article-title>
<source>World J Pediatr</source>
<year>2020</year>
<volume>16</volume>
<fpage>240</fpage>
<lpage>6</lpage>
</element-citation></ref>
<ref id="b16-cep-2025-00577">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Forrest</surname><given-names>CB</given-names></name>
<name><surname>Burrows</surname><given-names>EK</given-names></name>
<name><surname>Mejias</surname><given-names>A</given-names></name>
<name><surname>Razzahgi</surname><given-names>H</given-names></name>
<name><surname>Christakis</surname><given-names>D</given-names></name>
<name><surname>Jhaveri</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>Severity of acute COVID-19 in children &lt;18 years old March 2020 to December 2021</article-title>
<source>Pediatrics</source>
<year>2022</year>
<volume>149</volume>
<elocation-id>e2021055765</elocation-id>
</element-citation></ref>
<ref id="b17-cep-2025-00577">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Blanton</surname><given-names>D</given-names></name>
<name><surname>Han</surname><given-names>Z</given-names></name>
<name><surname>Bierschenk</surname><given-names>L</given-names></name>
<name><surname>Linga-Reddy</surname><given-names>MV</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Clare-Salzler</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes</article-title>
<source>Diabetes</source>
<year>2011</year>
<volume>60</volume>
<fpage>2566</fpage>
<lpage>70</lpage>
</element-citation></ref>
<ref id="b18-cep-2025-00577">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Han</surname><given-names>WG</given-names></name>
<name><surname>Hodemaekers</surname><given-names>HM</given-names></name>
<name><surname>Nagarajah</surname><given-names>B</given-names></name>
<name><surname>Poelen</surname><given-names>MM</given-names></name>
<name><surname>Helm</surname><given-names>K</given-names></name>
<name><surname>Janssen</surname><given-names>R</given-names></name>
<etal/>
</person-group>
<article-title>Association of vitamin D receptor polymorphism with susceptibility to symptomatic pertussis</article-title>
<source>PLoS One</source>
<year>2016</year>
<volume>11</volume>
<elocation-id>e0149576</elocation-id>
</element-citation></ref>
<ref id="b19-cep-2025-00577">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roth</surname><given-names>DE</given-names></name>
<name><surname>Jones</surname><given-names>AB</given-names></name>
<name><surname>Prosser</surname><given-names>C</given-names></name>
<name><surname>Robinson</surname><given-names>JL</given-names></name>
<name><surname>Vohra</surname><given-names>S</given-names></name>
</person-group>
<article-title>Vitamin D receptor polymorphisms and the risk of acute lower respiratory tract infection in early childhood</article-title>
<source>J Infect Dis</source>
<year>2008</year>
<volume>197</volume>
<fpage>676</fpage>
<lpage>80</lpage>
</element-citation></ref>
<ref id="b20-cep-2025-00577">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>S&#x000ee;rbe</surname><given-names>C</given-names></name>
<name><surname>Rednic</surname><given-names>S</given-names></name>
<name><surname>Grama</surname><given-names>A</given-names></name>
<name><surname>Pop</surname><given-names>TL</given-names></name>
</person-group>
<article-title>An update on the effects of vitamin D on the immune system and autoimmune diseases</article-title>
<source>Int J Mol Sci</source>
<year>2022</year>
<volume>23</volume>
<fpage>9784</fpage>
</element-citation></ref>
<ref id="b21-cep-2025-00577">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Panierakis</surname><given-names>C</given-names></name>
<name><surname>Goulielmos</surname><given-names>G</given-names></name>
<name><surname>Mamoulakis</surname><given-names>D</given-names></name>
<name><surname>Maraki</surname><given-names>S</given-names></name>
<name><surname>Papavasiliou</surname><given-names>E</given-names></name>
<name><surname>Galanakis</surname><given-names>E</given-names></name>
</person-group>
<article-title>Staphylococcus aureus nasal carriage might be associated with vitamin D receptor polymorphisms in type 1 diabetes</article-title>
<source>Int J Infect Dis</source>
<year>2009</year>
<volume>13</volume>
<fpage>e437</fpage>
<lpage>43</lpage>
</element-citation></ref>
<ref id="b22-cep-2025-00577">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zeidan</surname><given-names>NM</given-names></name>
<name><surname>Lateef</surname><given-names>HM</given-names></name>
<name><surname>Selim</surname><given-names>DM</given-names></name>
<name><surname>Razek</surname><given-names>SA</given-names></name>
<name><surname>Abd-Elrehim</surname><given-names>GA</given-names></name>
<name><surname>Nashat</surname><given-names>M</given-names></name>
<etal/>
</person-group>
<article-title>Vitamin D deficiency and vitamin D receptor FokI polymorphism as risk factors for COVID-19</article-title>
<source>Pediatr Res</source>
<year>2023</year>
<volume>93</volume>
<fpage>1383</fpage>
<lpage>90</lpage>
</element-citation></ref>
<ref id="b23-cep-2025-00577">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Etten</surname><given-names>E</given-names></name>
<name><surname>Verlinden</surname><given-names>L</given-names></name>
<name><surname>Giulietti</surname><given-names>A</given-names></name>
<name><surname>Ramos-Lopez</surname><given-names>E</given-names></name>
<name><surname>Branisteanu</surname><given-names>DD</given-names></name>
<name><surname>Ferreira</surname><given-names>GB</given-names></name>
<etal/>
</person-group>
<article-title>The vitamin D receptor gene FokI polymorphism: functional impact on the immune system</article-title>
<source>Eur J Immunol</source>
<year>2007</year>
<volume>37</volume>
<fpage>395</fpage>
<lpage>405</lpage>
</element-citation></ref>
<ref id="b24-cep-2025-00577">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kotur</surname><given-names>N</given-names></name>
<name><surname>Skakic</surname><given-names>A</given-names></name>
<name><surname>Klaassen</surname><given-names>K</given-names></name>
<name><surname>Gasic</surname><given-names>V</given-names></name>
<name><surname>Zukic</surname><given-names>B</given-names></name>
<name><surname>Skodric- Trifunovic</surname><given-names>V</given-names></name>
<etal/>
</person-group>
<article-title>Association of vitamin D, zinc and selenium related genetic variants with COVID-19 disease severity</article-title>
<source>Front Nutr</source>
<year>2021</year>
<volume>8</volume>
<fpage>689419</fpage>
</element-citation></ref>
<ref id="b25-cep-2025-00577">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miyamoto</surname><given-names>K</given-names></name>
<name><surname>Kesterson</surname><given-names>RA</given-names></name>
<name><surname>Yamamoto</surname><given-names>H</given-names></name>
<name><surname>Taketani</surname><given-names>Y</given-names></name>
<name><surname>Nishiwaki</surname><given-names>E</given-names></name>
<name><surname>Tatsumi</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Structural organization of the human vitamin D receptor chromosomal gene and its promoter</article-title>
<source>Mol Endocrinol</source>
<year>1997</year>
<volume>11</volume>
<fpage>1165</fpage>
<lpage>79</lpage>
</element-citation></ref>
<ref id="b26-cep-2025-00577">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mamurova</surname><given-names>B</given-names></name>
<name><surname>Akan</surname><given-names>G</given-names></name>
<name><surname>Mogol</surname><given-names>E</given-names></name>
<name><surname>Turgay</surname><given-names>A</given-names></name>
<name><surname>Tuncel</surname><given-names>G</given-names></name>
<name><surname>Evren</surname><given-names>EU</given-names></name>
<etal/>
</person-group>
<article-title>Strong association between vitamin D receptor gene and severe acute respiratory syndrome coronavirus 2 infectious variants</article-title>
<source>Glob Med Genet</source>
<year>2023</year>
<volume>10</volume>
<fpage>27</fpage>
<lpage>33</lpage>
</element-citation></ref>
<ref id="b27-cep-2025-00577">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Apaydin</surname><given-names>T</given-names></name>
<name><surname>Polat</surname><given-names>H</given-names></name>
<name><surname>Dincer Yazan</surname><given-names>C</given-names></name>
<name><surname>Ilgin</surname><given-names>C</given-names></name>
<name><surname>Elbasan</surname><given-names>O</given-names></name>
<name><surname>Dashdamirova</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Effects of vitamin D receptor gene polymorphisms on the prognosis of COVID-19</article-title>
<source>Clin Endocrinol (Oxf)</source>
<year>2022</year>
<volume>96</volume>
<fpage>819</fpage>
<lpage>30</lpage>
</element-citation></ref>
<ref id="b28-cep-2025-00577">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nagasawa</surname><given-names>H</given-names></name>
<name><surname>Sasaki</surname><given-names>H</given-names></name>
<name><surname>Uto</surname><given-names>Y</given-names></name>
<name><surname>Kubo</surname><given-names>S</given-names></name>
<name><surname>Hori</surname><given-names>H</given-names></name>
</person-group>
<article-title>Association of the macrophage activating factor (MAF) precursor activity with polymorphism in vitamin D-binding protein</article-title>
<source>Anticancer Res</source>
<year>2004</year>
<volume>24</volume>
<fpage>3361</fpage>
<lpage>6</lpage>
</element-citation></ref>
<ref id="b29-cep-2025-00577">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Speeckaert</surname><given-names>MM</given-names></name>
<name><surname>De Buyzere</surname><given-names>ML</given-names></name>
<name><surname>Delanghe</surname><given-names>JR</given-names></name>
</person-group>
<article-title>Vitamin D binding protein polymorphism and COVID-19</article-title>
<source>J Med Virol</source>
<year>2021</year>
<volume>93</volume>
<fpage>705</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b30-cep-2025-00577">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Karcioglu Batur</surname><given-names>L</given-names></name>
<name><surname>Hekim</surname><given-names>N</given-names></name>
</person-group>
<article-title>The role of DBP gene polymorphisms in the prevalence of new coronavirus disease 2019 infection and mortality rate</article-title>
<source>J Med Virol</source>
<year>2021</year>
<volume>93</volume>
<fpage>1409</fpage>
<lpage>13</lpage>
</element-citation></ref>
<ref id="b31-cep-2025-00577">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Karakukcu</surname><given-names>C</given-names></name>
<name><surname>Elibol</surname><given-names>A</given-names></name>
<name><surname>Eren</surname><given-names>E</given-names></name>
<name><surname>Saracoglu</surname><given-names>H</given-names></name>
<name><surname>Mutlu Sariguzel</surname><given-names>F</given-names></name>
<name><surname>Gorkem</surname><given-names>A</given-names></name>
<etal/>
</person-group>
<article-title>Evaluation of vitamin D binding protein and 25-hydroxy vitamin D metabolites in COVID-19 patients</article-title>
<source>Int J Med Biochem</source>
<year>2023</year>
<volume>6</volume>
<fpage>69</fpage>
<lpage>74</lpage>
</element-citation></ref>
<ref id="b32-cep-2025-00577">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Randolph</surname><given-names>AG</given-names></name>
<name><surname>Yip</surname><given-names>WK</given-names></name>
<name><surname>Falkenstein-Hagander</surname><given-names>K</given-names></name>
<name><surname>Weiss</surname><given-names>ST</given-names></name>
<name><surname>Janssen</surname><given-names>R</given-names></name>
<name><surname>Keisling</surname><given-names>S</given-names></name>
<etal/>
</person-group>
<article-title>Vitamin D-binding protein haplotype is associated with hospitalization for RSV bronchiolitis</article-title>
<source>Clin Exp Allergy</source>
<year>2014</year>
<volume>44</volume>
<fpage>231</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b33-cep-2025-00577">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Speeckaert</surname><given-names>MM</given-names></name>
<name><surname>Speeckaert</surname><given-names>R</given-names></name>
<name><surname>Delanghe</surname><given-names>JR</given-names></name>
</person-group>
<article-title>The biologic importance of the vitamin D binding protein polymorphism in pediatric COVID-19 patients</article-title>
<source>Eur J Pediatr</source>
<year>2021</year>
<volume>180</volume>
<fpage>2707</fpage>
<lpage>8</lpage>
</element-citation></ref>
<ref id="b34-cep-2025-00577">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lange</surname><given-names>CM</given-names></name>
<name><surname>Bojunga</surname><given-names>J</given-names></name>
<name><surname>Ramos-Lopez</surname><given-names>E</given-names></name>
<name><surname>von Wagner</surname><given-names>M</given-names></name>
<name><surname>Hassler</surname><given-names>A</given-names></name>
<name><surname>Vermehren</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy</article-title>
<source>J Hepatol</source>
<year>2011</year>
<volume>54</volume>
<fpage>887</fpage>
<lpage>93</lpage>
</element-citation></ref>
<ref id="b35-cep-2025-00577">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lopez</surname><given-names>ER</given-names></name>
<name><surname>Zwermann</surname><given-names>O</given-names></name>
<name><surname>Segni</surname><given-names>M</given-names></name>
<name><surname>Meyer</surname><given-names>G</given-names></name>
<name><surname>Reincke</surname><given-names>M</given-names></name>
<name><surname>Seissler</surname><given-names>J</given-names></name>
<etal/>
</person-group>
<article-title>A promoter polymorphism of the CYP27B1 gene is associated with Addison&#x00027;s disease, Hashimoto&#x00027;s thyroiditis, Graves&#x00027; disease and type 1 diabetes mellitus in Germans</article-title>
<source>Eur J Endocrinol</source>
<year>2004</year>
<volume>151</volume>
<fpage>193</fpage>
<lpage>7</lpage>
</element-citation></ref>
<ref id="b36-cep-2025-00577">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Awasthi</surname><given-names>N</given-names></name>
<name><surname>Awasthi</surname><given-names>S</given-names></name>
<name><surname>Pandey</surname><given-names>S</given-names></name>
</person-group>
<article-title>Role of VDR gene polymorphisms with community acquired pneumonia in North Indian children: a case-control study</article-title>
<source>Int J Mol Epidemiol Genet</source>
<year>2021</year>
<volume>12</volume>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation></ref>
<ref id="b37-cep-2025-00577">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Do&#x0011f;an</surname><given-names>D</given-names></name>
<name><surname>&#x000d6;zcan</surname><given-names>EG</given-names></name>
<name><surname>&#x000c7;ak&#x00131;r</surname><given-names>D&#x000dc;</given-names></name>
<name><surname>S&#x00131;lan</surname><given-names>F</given-names></name>
</person-group>
<article-title>Genetic influence on urinary vitamin D binding protein excretion and serum levels: a focus on rs4588 C&gt;A polymorphism in the GC gene</article-title>
<source>Front Endocrinol (Lausanne)</source>
<year>2023</year>
<volume>14</volume>
<fpage>1281112</fpage>
</element-citation></ref></ref-list>
<sec sec-type="display-objects">
<title>Figure and Tables</title>
<fig id="f1-cep-2025-00577" position="float">
<label>Fig. 1.</label><caption><p>Mean serum vitamin D binding protein (VDBP) level by Gc gene <italic>rs7041</italic> genotype.</p></caption>
<graphic xlink:href="cep-2025-00577f1.tif"/></fig>
<fig id="f2-cep-2025-00577" position="float">
<graphic xlink:href="cep-2025-00577f2.tif"/></fig>

<table-wrap id="t1-cep-2025-00577" position="float">
<label>Table 1.</label>
<caption><p>Demographic characteristics and clinical parameters of the COVID-19 versus control cases</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">Variable</th>
<th align="center" valign="middle">Index cases</th>
<th align="center" valign="middle">Control cases</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Age (yr)</td>
<td valign="top" align="center">5.22&#x000B1;5.47</td>
<td valign="top" align="center">5.75&#x000B1;5.03</td>
</tr>
<tr>
<td valign="top" align="left">Male sex</td>
<td valign="top" align="center">33 (55)</td>
<td valign="top" align="center">34 (56)</td>
</tr>
<tr>
<td valign="top" align="left">COVID-19 severity</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Mild</td>
<td valign="top" align="center">20 (33.3)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Moderate</td>
<td valign="top" align="center">30 (50)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Severe/critical</td>
<td valign="top" align="center">10 (16.7)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Main causes of admission</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Fever symptom &gt;38&#x000B0;C</td>
<td valign="top" align="center">48 (80)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Cough/rhinitis</td>
<td valign="top" align="center">47 (78.4)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Poor feeding/vomiting/diarrhea</td>
<td valign="top" align="center">21 (35)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Thoracic pain</td>
<td valign="top" align="center">5 (8,4)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Neurological symptoms</td>
<td valign="top" align="center">7 (11.7)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Lower respiratory symptoms and fever &gt;38&#x000B0;C</td>
<td valign="top" align="center">9 (15)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Dyspnea/hypoxia/respiratory distress requiring O<sub>2</sub> therapy</td>
<td valign="top" align="center">7 (11.6)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;Noninfectious reasons</td>
<td valign="top" align="center">0 (0)</td>
<td valign="top" align="center">60 (100)</td>
</tr>
<tr>
<td valign="top" align="left">Mean duration of hospitalization (day)</td>
<td valign="top" align="center">4.13</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">PICU admission</td>
<td valign="top" align="center">2 (3.3)</td>
<td valign="top" align="center">-</td>
</tr>
<tr>
<td valign="top" align="left">Mortality</td>
<td valign="top" align="center">0 (0)</td>
<td valign="top" align="center"></td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>Values are presented as mean&#x000B1;standard deviation or number (%).</p>
<p>COVID-19, coronavirus disease 2019; PICU, pediatric intensive care unit.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t2-cep-2025-00577" position="float">
<label>Table 2.</label>
<caption><p>Association between VDR <italic>FokI, TaqI,</italic> Gc (<italic>rs7041</italic>), and CYP27B1-1260 genotypes and COVID-19 severity</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle">SNP genotypes</th>
<th align="center" valign="middle">Mild disease group (n=20) (%)</th>
<th align="center" valign="middle">Moderate/severe disease group (n=40) (%)</th>
<th align="center" valign="middle">Analysis model</th>
<th align="center" valign="middle">OR (95% CI)</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">VDR <italic>FokI</italic> genotype (F/f)</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center">Dominant (<italic>FF</italic> vs. <italic>Ff</italic> vs. <italic>ff</italic>)</td>
<td valign="top" align="center">0.215 (0.054&#x02013;0.854)</td>
<td valign="top" align="center"><bold>0.028</bold></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>FF</italic></td>
<td valign="top" align="center">85</td>
<td valign="top" align="center">55</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>Ff</italic></td>
<td valign="top" align="center">10</td>
<td valign="top" align="center">37.5</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>ff</italic></td>
<td valign="top" align="center">5</td>
<td valign="top" align="center">7.5</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">VDR <italic>TaqI</italic> genotype (T/t)</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center">Dominant (<italic>TT</italic> vs. <italic>Tt</italic> vs. <italic>tt</italic>)</td>
<td valign="top" align="center">3.000 (0.915&#x02013;9.830)</td>
<td valign="top" align="center">0.069</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>TT</italic></td>
<td valign="top" align="center">25</td>
<td valign="top" align="center">50</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>Tt</italic></td>
<td valign="top" align="center">45</td>
<td valign="top" align="center">30</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>tt</italic></td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">20</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">Gc (<italic>rs7041</italic>) genotype (T/G)</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center">Recessive (<italic>GG</italic> vs. <italic>TG+TT</italic>)</td>
<td valign="top" align="center">0.316 (0.101&#x02013;0.994)</td>
<td valign="top" align="center"><bold>0.048</bold></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>TT</italic></td>
<td valign="top" align="center">0</td>
<td valign="top" align="center">7.5</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>TG</italic></td>
<td valign="top" align="center">30</td>
<td valign="top" align="center">50</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>GG</italic></td>
<td valign="top" align="center">70</td>
<td valign="top" align="center">42.5</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">CYP27B1-1260 (<italic>rs10877012</italic>) genotype (A/C)</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center">Recessive (<italic>CC</italic> vs. <italic>AC+AA</italic>)</td>
<td valign="top" align="center">0.305 (0.086&#x02013;1.077)</td>
<td valign="top" align="center">0.065</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>AA</italic></td>
<td valign="top" align="center">10</td>
<td valign="top" align="center">5</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>AC</italic></td>
<td valign="top" align="center">10</td>
<td valign="top" align="center">40</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>CC</italic></td>
<td valign="top" align="center">80</td>
<td valign="top" align="center">55</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>VDR, vitamin D receptor; COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism.</p>
<p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>

<table-wrap id="t3-cep-2025-00577" position="float">
<label>Table 3.</label>
<caption><p>Uni- and multivariate analyses of correlations between VDR <italic>FokI</italic> genotypes and COVID-19 susceptibility and severity</p></caption>
<table rules="groups" frame="hsides">
<thead><tr>
<th align="left" valign="middle" rowspan="2">Variable</th>
<th align="center" valign="middle" colspan="2">Univariable analysis<hr/></th>
<th align="center" valign="middle" colspan="2">Multivariable analysis<hr/></th>
</tr><tr>
<th align="center" valign="middle">OR (95% CI), unadjusted</th>
<th align="center" valign="middle"><italic>P</italic> value</th>
<th align="center" valign="middle">OR (95% CI), adjusted<sup><xref rid="tfn1-cep-2025-00577" ref-type="table-fn">a)</xref></sup></th>
<th align="center" valign="middle"><italic>P</italic> value</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left">COVID-19 susceptibility</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>FokI</italic> dominant (<italic>FF</italic> vs. <italic>Ff </italic>vs. <italic>ff</italic>) model</td>
<td valign="top" align="center">2.269 (1.088-4.733)</td>
<td valign="top" align="center">0.028<sup>b)</sup></td>
<td valign="top" align="center">2.11 (0.957-4.6515)</td>
<td valign="top" align="center">0.064</td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;VDR <italic>FokI</italic> allele (F vs. f)</td>
<td valign="top" align="center">2.046 (1.147-3.649)</td>
<td valign="top" align="center">0.015<sup>b)</sup></td>
<td valign="top" align="center">1.9112 (1.0156-3.596)</td>
<td valign="top" align="center"><bold>0.044</bold></td>
</tr>
<tr>
<td valign="top" align="left">COVID-19 severity</td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
<td valign="top" align="center"></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;<italic>FokI</italic> Dominant (<italic>FF</italic> vs. <italic>Ff</italic> vs. <italic>ff</italic>) model</td>
<td valign="top" align="center">0.215 (0.054-0.854)</td>
<td valign="top" align="center">0.028<sup>b)</sup></td>
<td valign="top" align="center">0.201 (0.049-0.8315)</td>
<td valign="top" align="center"><bold>0.027</bold></td>
</tr>
<tr>
<td valign="top" align="left">&#x02003;VDR <italic>FokI</italic> allele (<italic>F</italic> vs. <italic>f</italic>)</td>
<td valign="top" align="center">3.203 (1.017-10.084)</td>
<td valign="top" align="center">0.046<sup>b)</sup></td>
<td valign="top" align="center">3.316 (1.026-10.709)</td>
<td valign="top" align="center"><bold>0.045</bold></td>
</tr>
</tbody></table>
<table-wrap-foot>
<fn><p>VDR, vitamin D receptor; COVID-19, coronavirus disease 2019; OR, odds ratio; CI, confidence interval.</p></fn>
<fn id="tfn1-cep-2025-00577"><label>a)</label><p>Adjusted for age, sex and comorbidities.</p></fn>
<fn><p>Boldface indicates a statistically significant difference with <italic>P</italic>&lt;0.05.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
</back></article>